相关临床试验
14
0 进行中
药物批准
6
批准总数
监管机构
2
监管机构数
成立时间
N/A
已完成
11
78.6%
招募中
3
21.4%
- Bracco Imaging and NYU Langone Health signed a multi-year Master Research Agreement to accelerate development of advanced imaging technologies including MRI, CT, ultrasound and PET/CT. - The collaboration will focus on Photon-Counting Computed Tomography, targeted ultrasound, and artificial intelligence-enabled PET/CT and MRI image analysis to support precision medicine. - The partnership aims to enhance diagnostic performance, streamline clinical workflows, and facilitate translation of scientific discoveries into real-world healthcare applications. - NYU Langone Health has been ranked No. 1 out of 118 comprehensive academic medical centers for four consecutive years by Vizient, Inc.
- The FDA has approved flotufolastat F 18 injection (Posluma) for PET imaging of PSMA-positive lesions in prostate cancer patients, aiding in metastasis detection and recurrence assessment. - Posluma, developed by Blue Earth Diagnostics, utilizes radiohybrid technology to target PSMA, offering high specificity and detection rates, even at low PSA levels, as shown in LIGHTHOUSE and SPOTLIGHT trials. - Clinical trials demonstrated Posluma's ability to accurately identify pelvic lymph nodes and distant metastatic lesions, with a high overall patient-level detection rate of 99% in recurrence cases. - The agent, expected to be commercially available in June 2023, offers a new tool for physicians in managing prostate cancer by improving the detection and localization of the disease.
